fluorescent pewarna sel-sel kanker otak--T-REC-komunitas reptil-semarang--KSE-komunitas satwa eksotik

SILAHKAN MENGGUNAKAN " MESIN TRANSLATE "..GOOGLE TRANSLATE 
DISAMPING KANAN INI............. 

PLEASE USE ........ "TRANSLATE MACHINE" .. GOOGLE TRANSLATE BESIDE RIGHT THIS

................. 

T-REC -TUGUMUDA REPTILES COMMUNITY-INDONESIA

 

More info :

www.trecsemarang2011.blogspot.com

minat gabung : ( menerima keanggotaan seluruh kota dan daerah di Indonesia )

08995557626

..................................

KSE – KOMUNITAS SATWA EKSOTIK – EXOTIC PETS COMMUNITY-- INDONESIA

Visit Our Community and Joint W/ Us....Welcome All Over The World

www.facebook.com/groups/komunitassatwaeksotik/

 KSE = KOMUNITAS SATWA EKSOTIK

MENGATASI KENDALA MINAT DAN JARAK

KAMI ADA DI TIAP KOTA DI INDONESIA 

DETAIL TENTANG KSE-----KLIK : www.komunitassatwaeksotik-pendaftaran.blogspot.com 

GABUNG......... ( menerima keanggotaan seluruh kota dan daerah di Indonesia )

HUBUNGI   :  089617123865

.........................

fluorescent pewarna sel-sel kanker otak

Dua pewarna fluorescent baru tertarik pada sel-sel kanker dapat membantu ahli bedah saraf  lebih akurat melokalisir dan benar-benar reseksi tumor otak , sebuah studi baru  menunjukkan..... Menghapus semua daerah yang  terlihat kanker ( reseksi gross  total) secara signifikan meningkatkan kelangsungan hidup setelah operasi kanker otak ....read more

Fluorescent dyes
'light up' brain cancer cells

Date:

January 30, 2015

Source:

Wolters Kluwer Health:
Lippincott Williams and Wilkins

Summary:

Two new fluorescent
dyes attracted to cancer cells may help neurosurgeons more accurately localize
and completely resect brain tumors, suggests a new study. Removing all visible
areas of cancer (gross total resection) significantly improves survival after
brain cancer surgery.

........................

two new fluorescent dyes
attracted to cancer cells may help neurosurgeons more accurately localize and
completely resect brain tumors, suggests a study in the February issue of Neurosurgery,
official journal of the Congress of Neurological Surgeons. The journal is
published by Lippincott Williams & Wilkins, a part of Wolters Kluwer
Health.

Dr. John S. Kuo and colleagues of University of Wisconsin School of
Medicine and Public Health, Madison, evaluated two "tumor-selective"
fluorescent agents -- called CLR1501 and CLR1502 -- for their ability to
differentiate brain tumors from normal brain tissue in mice. "This study
demonstrates the promising potential of CLR1501 and CLR 1502 analogs for use in
fluorescence-guided tumor surgery," the researchers conclude.

Green and Near-Infrared Fluorescent Dyes Make Cancer Cells Glow

CLR1501 and CLR1502 are synthetic analogs of the tumor-targeting agent
alkylphosphocholine (APC), which is specifically attracted to cancer cells. The
new agents were molecularly altered to carry fluorescent dyes that glow under
lights with specific wavelengths -- either in the green (CLR1501) or
near-infrared (CLR1502) range. Viewed under appropriate conditions, the dyes
make tumor cells "light up" so that they can be readily distinguished
from neighboring normal brain tissue.

Using different types of imaging technologies, Dr. Kuo and colleagues
evaluated the ability of CLR1501 and CLR1502 to detect implanted (xenograft)
tumors in mice. The results were compared with imaging studies performed with a
dye called 5-aminolevulinic acid (5-ALA), which glows under blue light.
Although 5-ALA is used for fluorescence-guided neurosurgery in Europe, it is
not yet approved for routine use in the United States.

The results confirmed that CLR1501 and CLR1502 were attracted to tumor
cells, and emitted light of specific wavelengths under appropriate imaging
conditions. Both APC analogs provided "excellent fluorescence
discrimination of tumor from adjacent normal brain." Tumors could be
clearly seen using different types of commercially available imaging systems.

Imaging with CLR1501 green dye showed fluorescence similar to that achieved
with currently used 5-ALA dye. With the near-infrared CLR1502 dye, fluorescence
was even greater than with 5-ALA. The use of near-infrared fluorescence would
offer additional advantages during actual surgery, compared to fluorescence in
the visible-light range.

With Possible Uses in Guiding Brain Cancer Surgery

The findings build on previous cellular-level studies suggesting that APC analogs
might be useful in guiding brain cancer surgery. Used during surgery for brain
cancer, these fluorescent dyes could help neurosurgeons to locate the tumor and
to resect it as completely as possible. Removing all visible areas of cancer
(gross total resection) significantly improves survival after brain cancer
surgery.

In preliminary studies, near-infrared imaging with CLR1502 successfully
localized brain tumors through the intact skin and skull of living mice. In
addition to fluorescent-guided neurosurgery, APC analogs might play useful
roles in diagnosing brain cancers and in targeting chemotherapy drugs directly
to cancer cells.

The researchers acknowledge the "inherent limitations" of their
experiments, limited to implanted tumors in animals. Further research will be
needed to assess issues related to dye administration, visualization, and
timing, as well as the optimal technologies for practical use during surgery.
Dr. Kuo and coauthors write, "[U]pcoming clinical trials in human tumors
are planned for these promising tumor-selective fluorescence agents."







Story Source:

The above story is based on materials provided by Wolters
Kluwer Health: Lippincott Williams and Wilkins. Note: Materials may be edited
for content and length.







Journal Reference:

1.    Kyle I. Swanson, Paul A. Clark, Ray R.
Zhang, Irawati K. Kandela, Mohammed Farhoud, Jamey P. Weichert, John S.
Kuo. Fluorescent Cancer-Selective Alkylphosphocholine Analogs for
Intraoperative Glioma Detection.Neurosurgery, 2015; 76 (2): 115
DOI: 10.1227/NEU.0000000000000622

http://www.sciencedaily.com/releases/2015/01/150130121617.htm







-b) � m 0 (�>  `4 -bottom:.0001pt;line-height:
13.35pt;background:white'>Results from trials of the monovalent vaccine in Mali and Switzerland are
expected shortly.




The safety and immunogenicity data from the Oxford trial supports the move
into much larger scale studies in West Africa, testing vaccine effectiveness to
prevent Ebola virus disease.

The Oxford University scientists have also begun testing the safety of a
candidate booster vaccine against Ebola, to find out whether it could further
increase the immune responses.

30 of the original volunteers have been invited back and received a second
candidate Ebola vaccine of a different type made by Bavarian Nordic, a company
based in Denmark. Ongoing trials in Oxford are still seeking to assess further
this two-dose regime. Anyone interested in volunteering should contact vaccinetrials@ndm.ox.ac.uk.

Professor Hill said: 'The speed at which all this is happening is
remarkable. We'd especially like to thank all the volunteers. They continue to
take time out of their busy lives to give blood samples at regular intervals so
we can understand more about their immune responses having received the
vaccine. It's also thanks to the hard work of many scientists, funders, pharma
firms, regulators and agencies, all coming together, that we can make such
rapid progress.'

He added: 'Whether we have a vaccine that is safe, effective and works, we
won't know for a while yet. But we owe it to the people who have been affected
so badly by the Ebola outbreak to find out.'

International Development Secretary Justine Greening said: 'Britain is a
world leader in medical research and the outcome of these DFID-funded trials
takes us a step closer to finding a vaccine that could help contain Ebola and
prevent future outbreaks.

'I would like to thank the volunteers who took part in this important
trial. They join thousands of British doctors, nurses, military personnel,
scientists and aid workers in the fight against this terrible disease.'

Dr Jeremy Farrar, Director of the Wellcome Trust, said: 'This study is very
encouraging as it provides good initial evidence that the GSK vaccine will be
safe to use in people. However, we still don't know whether it will provide
protection against Ebola infection in a real-world situation. That's why trials
in West Africa of this, and the other vaccines in development, must begin as
soon possible. This has been an amazing global collaboration which we are proud
to have supported.

'Falling infection rates in many of the affected regions increase the
urgency of this research. While it is wonderful news that the epidemic is
slowing in all three affected countries we cannot consider the crisis over
until there are no more people infected by Ebola across the whole region of
West Africa. Vaccines may yet play a crucial role in achieving this, and will
undoubtedly play a crucial role in protecting against future outbreaks of the
virus.'







Story Source:

The above story is based on materials provided by University
of Oxford. Note: Materials may be edited for content and length.







Journal Reference:

1.    Tommy Rampling, Katie Ewer, Georgina
Bowyer, Danny Wright, Egeruan B. Imoukhuede, Ruth Payne, Felicity Hartnell,
Malick Gibani, Carly Bliss, Alice Minhinnick, Morven Wilkie, Navin Venkatraman,
Ian Poulton, Natalie Lella, Rachel Roberts, Kailan Sierra-Davidson, Verena
Krähling, Eleanor Berrie, Francois Roman, Iris De Ryck, Alfredo Nicosia, Nancy
J. Sullivan, Daphne A. Stanley, Julie E. Ledgerwood, Richard M. Schwartz,
Loredana Siani, Stefano Colloca, Antonella Folgori, Stefania Di Marco, Riccardo
Cortese, Stephan Becker, Barney S. Graham, Richard A. Koup, Myron M. Levine,
Vasee Moorthy, Andrew J. Pollard, Simon J. Draper, W. Ripley Ballou, Alison
Lawrie, Sarah C. Gilbert, Adrian V.S. Hill. A Monovalent Chimpanzee
Adenovirus Ebola Vaccine — Preliminary Report.New England Journal of
Medicine, 2015; 150128140051005 DOI:10.1056/NEJMoa1411627

http://www.sciencedaily.com/releases/2015/01/150129094355.htm

Share this: